CY1109877T1 - Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου - Google Patents

Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου

Info

Publication number
CY1109877T1
CY1109877T1 CY20101100198T CY101100198T CY1109877T1 CY 1109877 T1 CY1109877 T1 CY 1109877T1 CY 20101100198 T CY20101100198 T CY 20101100198T CY 101100198 T CY101100198 T CY 101100198T CY 1109877 T1 CY1109877 T1 CY 1109877T1
Authority
CY
Cyprus
Prior art keywords
antibodies
petidium
amyloides
beta
amyloid
Prior art date
Application number
CY20101100198T
Other languages
English (en)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1109877T1 publication Critical patent/CY1109877T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Αντισώματα που συνδέουν ανθρώπινο β-αμυλοειδές πεπτίδιο, μέθοδο θεραπείας ασθενειών ή διαταραχών που χαρακτηρίζονται από αυξημένα επίπεδα β-αμυλοειδούς ή αποθέσεις β-αμυλοειδούς με τα εν λόγω αντισώματα, φαρμακευτικές συνθέσεις που περιλαμβάνουν τα εν λόγω αντισώματα και μεθόδους βιομηχανικής κατασκευής.
CY20101100198T 2006-03-30 2010-03-01 Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου CY1109877T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
EP07727401A EP1996621B1 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
CY1109877T1 true CY1109877T1 (el) 2014-09-10

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100198T CY1109877T1 (el) 2006-03-30 2010-03-01 Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου

Country Status (33)

Country Link
US (3) US8227576B2 (el)
EP (2) EP2177536B1 (el)
JP (1) JP5103466B2 (el)
KR (2) KR20120093400A (el)
CN (2) CN101415729B (el)
AR (1) AR060332A1 (el)
AT (1) ATE451392T1 (el)
AU (1) AU2007233831B2 (el)
BR (1) BRPI0709246A2 (el)
CA (1) CA2647808C (el)
CR (1) CR10347A (el)
CY (1) CY1109877T1 (el)
DE (1) DE602007003703D1 (el)
DK (2) DK1996621T3 (el)
EA (1) EA015654B9 (el)
ES (2) ES2484967T3 (el)
HK (2) HK1138015A1 (el)
HR (2) HRP20100115T1 (el)
IL (1) IL193695A (el)
JO (1) JO2576B1 (el)
MA (1) MA30337B1 (el)
MX (1) MX2008012483A (el)
MY (1) MY149630A (el)
NO (1) NO20083793L (el)
NZ (1) NZ571038A (el)
PE (1) PE20080181A1 (el)
PL (2) PL2177536T3 (el)
PT (2) PT2177536E (el)
SI (2) SI1996621T1 (el)
TW (1) TWI385179B (el)
UA (1) UA94734C2 (el)
WO (1) WO2007113172A2 (el)
ZA (1) ZA200807911B (el)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2182983B1 (en) * 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
CA2695484C (en) * 2007-08-20 2018-05-01 Glaxo Group Limited Production method of therapeutic proteins based on codon adaptation
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
BRPI0818621A8 (pt) * 2007-10-05 2018-01-30 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
EP2592147A1 (en) * 2007-10-12 2013-05-15 F. Hoffmann-La Roche AG Protein expression from multiple nucleic acids
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
MX2010006422A (es) * 2007-12-11 2010-06-25 Glaxo Group Ltd Proteinas de union a antigenos.
WO2009085200A2 (en) * 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2441447A1 (en) 2008-05-06 2012-04-18 Glaxo Group Limited Encapsulation of biologically active agents
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
CA2766537A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
BR112012022102A2 (pt) 2010-03-03 2017-01-10 Boehringer Ingelheim Int polipeptídeos de ligação a a-beta.
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
CN103443125B (zh) * 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2852618A2 (en) 2012-05-21 2015-04-01 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
US20160139118A1 (en) 2013-06-19 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
MX2019015914A (es) 2017-06-29 2020-08-06 Univ Columbia Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3819311A4 (en) * 2018-07-17 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. ANTI-ABETA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF
JP2022528953A (ja) 2019-04-05 2022-06-16 タウク３ バイオロジクス リミテッド 抗タウｃ３抗体及びその使用
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
NZ337765A (en) * 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
AU4178601A (en) * 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法

Also Published As

Publication number Publication date
CA2647808C (en) 2015-11-17
CA2647808A1 (en) 2007-10-11
US8227576B2 (en) 2012-07-24
SI2177536T1 (sl) 2014-09-30
AU2007233831A1 (en) 2007-10-11
US9193784B2 (en) 2015-11-24
JO2576B1 (en) 2011-02-27
CN103539857A (zh) 2014-01-29
MY149630A (en) 2013-09-13
EP2177536B1 (en) 2014-06-04
KR20080113273A (ko) 2008-12-29
ES2338179T3 (es) 2010-05-04
HK1122311A1 (en) 2009-05-15
CN101415729A (zh) 2009-04-22
TWI385179B (zh) 2013-02-11
AR060332A1 (es) 2008-06-11
IL193695A (en) 2012-05-31
DK2177536T3 (da) 2014-07-14
EA200801842A1 (ru) 2009-02-27
ATE451392T1 (de) 2009-12-15
PT2177536E (pt) 2014-08-22
IL193695A0 (en) 2011-08-01
EA015654B9 (ru) 2012-01-30
DK1996621T3 (da) 2010-04-19
JP5103466B2 (ja) 2012-12-19
HK1138015A1 (en) 2010-08-13
ES2484967T3 (es) 2014-08-12
PE20080181A1 (es) 2008-03-16
BRPI0709246A2 (pt) 2011-07-12
PT1996621E (pt) 2010-03-08
KR101263294B1 (ko) 2013-06-04
SI1996621T1 (sl) 2010-04-30
EP2177536A1 (en) 2010-04-21
MA30337B1 (fr) 2009-04-01
NZ571038A (en) 2011-03-31
US20160024197A1 (en) 2016-01-28
NO20083793L (no) 2008-10-13
CN101415729B (zh) 2013-09-04
JP2009531380A (ja) 2009-09-03
US20140050719A1 (en) 2014-02-20
UA94734C2 (ru) 2011-06-10
KR20120093400A (ko) 2012-08-22
TW200815466A (en) 2008-04-01
ZA200807911B (en) 2009-11-25
EA015654B1 (ru) 2011-10-31
PL1996621T3 (pl) 2010-05-31
HRP20100115T1 (hr) 2010-04-30
EP1996621A2 (en) 2008-12-03
HRP20140618T1 (hr) 2014-08-15
WO2007113172A2 (en) 2007-10-11
WO2007113172A3 (en) 2007-11-29
AU2007233831B2 (en) 2013-02-14
MX2008012483A (es) 2008-10-10
US20110142824A1 (en) 2011-06-16
CR10347A (es) 2008-10-29
DE602007003703D1 (de) 2010-01-21
PL2177536T3 (pl) 2014-11-28
EP1996621B1 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
CY1122428T1 (el) Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1125436T1 (el) Αναστολεις dna-pk
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
CY1125133T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
AR128047A2 (es) Moléculas de anticuerpos que se unen a il-17a e il-17f
CY1122073T1 (el) Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
EA202090338A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CR20130624A (es) Proteínas de unión a antígeno
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA200901211A1 (ru) Антигены белка с5 и их применение